Drug Trial Radar · NCT07454291
A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants
Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
57
Planned (sponsor's estimate)
Start
Apr 28, 2026
Primary completion
Oct 2026
Study completion Oct 2026
Sponsor
- Lead sponsor
- Endeavor Biomedicines, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 26 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purposes of this study are to: 1. evaluate potential interactions between taladegib (ENV-101) and current standard-of-care (SOC) therapies for idiopathic pulmonary fibrosis (IPF), including nintedanib and pirfenidone, and 2. more fully characterize the pharmacokinetics (PK) of taladegib (i.e., how the body absorbs, distributes, metabolizes and excretes taladegib). This study will enroll 4 cohorts (groups) of participants. Each cohort will experience a different duration of treatment and sequestering (being housed) at the clinical site, followed by a 14-day follow-up period for safety evaluation. The longest duration of treatment for any cohort is 30 days.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
taladegibDrug
low, medium or high dose tablet administered once, or once a day
nintedanibDrug
150 mg capsule administered twice a day
pirfenidoneDrug
One, two or three 267 mg tablets administered three times a day
pirfenidoneDrug
Three 267 mg tablets administered once
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1: Taladegib (ENV-101) maximum blood concentration (Cmax) after administration alone and after coadministration with nintedanibTime frame: Day 1 and Day 13
- Cohort 1: Time of taladegib maximum blood concentration (Tmax) after administration alone and after coadministration with nintedanibTime frame: Day 1 and Day 13
- Cohort 1: Taladegib absorption to time t (AUC[0-t]) after administration alone and after coadministration with nintedanibTime frame: Day 1 and Day 13
- Cohort 1: Taladegib total absorption (AUC[0-infinity]) after administration alone and after coadministration with nintedanibTime frame: Day 1 and Day 13
- Cohort 1: Taladegib extrapolated total absorption (AUC[extrapolated]) after administration alone and after coadministration with nintedanibTime frame: Day 1 and Day 13
- Cohort 1: Taladegib half-life in the blood (T1/2) after administration alone and after coadministration with nintedanibTime frame: Day 1 and Day 13
- Cohort 1: Elimination rate constant (K[el]) for taladegib after administration alone and after coadministration with nintedanibTime frame: Day 1 and Day 13
- Cohort 1: Apparent oral clearance (CL/F) of taladegib after administration alone and after coadministration with nintedanibTime frame: Day 1 and Day 13
- Cohort 1: Apparent volume of distribution (Vz/F) of taladegib after administration alone and after coadministration with nintedanibTime frame: Day 1 and Day 13
- Cohort 2: Taladegib maximum blood concentration (Cmax) after administration alone and after coadministration with pirfenidoneTime frame: Day 1 and Day 27
- Cohort 2: Time of taladegib maximum blood concentration (Tmax) after administration alone and after coadministration with pirfenidoneTime frame: Day 1 and Day 27
- Cohort 2: Taladegib absorption to time t (AUC[0-t]) after administration alone and after coadministration with pirfenidoneTime frame: Day 1 and Day 27
- Cohort 2: Taladegib total absorption (AUC[0-infinity]) after administration alone and after coadministration with pirfenidoneTime frame: Day 1 and Day 27
- Cohort 2: Taladegib extrapolated total absorption (AUC[extrapolated]) after administration alone and after coadministration with pirfenidoneTime frame: Day 1 and Day 27
- Cohort 2: Taladegib half-life in the blood (T1/2) after administration alone and after coadministration with pirfenidoneTime frame: Day 1 and Day 27
- Cohort 2: Elimination rate constant (K[el]) for taladegib after administration alone and after coadministration with pirfenidoneTime frame: Day 1 and Day 27
- Cohort 2: Apparent oral clearance (CL/F) of taladegib after administration alone and after coadministration with pirfenidoneTime frame: Day 1 and Day 27
- Cohort 2: Apparent volume of distribution (Vz/F) of taladegib after administration alone and after coadministration with pirfenidoneTime frame: Day 1 and Day 27
- Cohort 3: Pirfenidone maximum blood concentration (Cmax) after administration alone and after coadministration with taladegibTime frame: Day 1 and Day 6
- Cohort 3: Time of pirfenidone maximum blood concentration (Tmax) after administration alone and after coadministration with taladegibTime frame: Day 1 and Day 6
- Cohort 3: Pirfenidone absorption to time t (AUC[0-t]) after administration alone and after coadministration with taladegibTime frame: Day 1 and Day 6
- Cohort 3: Pirfenidone total absorption (AUC[0-infinity]) after administration alone and after coadministration with taladegibTime frame: Day 1 and Day 6
- Cohort 3: Pirfenidone extrapolated total absorption (AUC[extrapolated]) after administration alone and after coadministration with taladegibTime frame: Day 1 and Day 6
- Cohort 3: Pirfenidone half-life in the blood (T1/2) after administration alone and after coadministration with taladegibTime frame: Day 1 and Day 6
- Cohort 3: Elimination rate constant (K[el]) for pirfenidone after administration alone and after coadministration with taladegibTime frame: Day 1 and Day 6
- Cohort 3: Apparent oral clearance (CL/F) of pirfenidone after administration alone and after coadministration with taladegibTime frame: Day 1 and Day 6
- Cohort 3: Apparent volume of distribution (Vz/F) of pirfenidone after administration alone and after coadministration with taladegibTime frame: Day 1 and Day 6
- Cohort 4: Taladegib maximum blood concentration (Cmax) after administration aloneTime frame: Day 1
- Cohort 4: Time of taladegib maximum blood concentration (Tmax) after administration aloneTime frame: Day 1
- Cohort 4: Taladegib absorption to time t (AUC[0-t]) after administration aloneTime frame: Day 1
- Cohort 4: Taladegib total absorption (AUC[0-infinity]) after administration aloneTime frame: Day 1
- Cohort 4: Taladegib extrapolated total absorption (AUC[extrapolated]) after administration aloneTime frame: Day 1
- Cohort 4: Taladegib half-life in the blood (T1/2) after administration aloneTime frame: Day 1
- Cohort 4: Elimination rate constant (K[el]) for taladegib after administration aloneTime frame: Day 1
- Cohort 4: Apparent oral clearance (CL/F) of taladegib after administration aloneTime frame: Day 1
- Cohort 4: Apparent volume of distribution (Vz/F) of taladegib after administration aloneTime frame: Day 1
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Brisbane, Queensland, Australia · Recruiting
Research Site
Melbourne, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.